Psoriasis management tree based on comorbidity

被引:0
|
作者
Amara, Shivkar [1 ]
Pasumarthi, Anusha [1 ]
Parikh, Neil [2 ]
Kodali, Nilesh [3 ]
Lebwohl, Mark [1 ]
Monks, George [4 ]
机构
[1] Icahn Sch Med Mt Sinai, Kimberly & Eric J Waldman Dept Dermatol, New York, NY 10029 USA
[2] Boston Univ, Chobanian & Avedisian Sch Med, Boston, MA USA
[3] Rugters New Jersey Med Sch, Newark, NJ USA
[4] Univ Oklahoma, Coll Med, Dept Dermatol, Oklahoma City, OK USA
关键词
psoriasis; psoriatic arthritis; biological agents; therapies; comorbidities; LONG-TERM SAFETY; ACTIVE CROHNS-DISEASE; NECROSIS-FACTOR-ALPHA; INFLAMMATORY-BOWEL-DISEASE; SEVERE PLAQUE PSORIASIS; QUALITY-OF-LIFE; DOUBLE-BLIND; CERTOLIZUMAB PEGOL; PHASE-III; MAINTENANCE THERAPY;
D O I
10.1111/ijd.17497
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriasis, a common chronic inflammatory skin disorder, encompasses various subtypes, including guttate, pustular, erythrodermic, and the most common type, plaque psoriasis. Irrespective of the subtype, psoriasis can manifest with multisystemic presentations, including psoriatic arthritis, metabolic disorders, cardiovascular disease, malignancies, chronic kidney disease (CKD), psychiatric illness, and inflammatory bowel disease (IBD). Many comorbidities and concomitant conditions must be considered when selecting the most appropriate therapy for a patient (Kaushik et al., 2019 and Monks et al., 2021) . Ongoing clinical trials and the development of new therapeutic targets contribute to the continuous improvement of available treatment options. Given the dynamic landscape of therapies, particularly when managing complex patients with multiple comorbidities, dermatologists are constantly challenged with the task of adeptly tailoring treatments to each psoriasis patient. This article systematically reviews the current evidence, presenting it as an updated Psoriasis Decision Tree to assist physicians in selecting tailored treatment options.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Psoriasis comorbidity management in the COVID era: a pressing challenge
    Song, Yang
    Yao, Lei
    Li, Shanshan
    Zhou, Junfeng
    FRONTIERS IN MICROBIOLOGY, 2023, 14
  • [2] PSORIASIS AND COMORBIDITY
    Liubiankova, Veranika
    Makarava, Sviatlana
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 6 - 6
  • [3] Comorbidity in psoriasis
    Gerdes, S.
    Mrowietz, U.
    Boehncke, W. -H.
    HAUTARZT, 2016, 67 (06): : 438 - 444
  • [4] Comorbidity and psoriasis
    Carranza Romero, C.
    Fernandez Vozmediano, J. M.
    Armario Hita, J. C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 : 58 - 58
  • [5] Consensus Statement on the Management of Comorbidity in Patients with Rheumatoid Arthritis and Psoriasis
    Castaneda, Santos
    Loza, Estibaliz
    Dauden, Esteban
    Carmona, Loreto
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (05) : 990 - 991
  • [6] A comorbidity-centered approach to psoriasis management: reflections and future directions
    Narang, Tarun
    Mehta, Hitaishi
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024,
  • [7] Association of Psoriasis With Comorbidity Development in Children With Psoriasis
    Tollefson, Megha M.
    Van Houten, Holly K.
    Asante, Dennis
    Yao, Xiaoxi
    Kremers, Hilal Maradit
    JAMA DERMATOLOGY, 2018, 154 (03) : 286 - 292
  • [8] Exploring the comorbidity mechanisms between psoriasis and obesity based on bioinformatics
    Gao, Changyong
    Li, Jianhong
    SKIN RESEARCH AND TECHNOLOGY, 2024, 30 (02)
  • [9] Psoriasis as a comorbidity of hidradenitis suppurativa
    Andersen, Rune Kjaersgaard
    Saunte, Sara K.
    Jemec, Gregor B. E.
    Saunte, Ditte M.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2020, 59 (02) : 216 - 220
  • [10] Epidemiology and comorbidity of psoriasis in children
    Augustin, M.
    Glaeske, G.
    Radtke, M. A.
    Christophers, E.
    Reich, K.
    Schaefer, I.
    BRITISH JOURNAL OF DERMATOLOGY, 2010, 162 (03) : 633 - 636